<DOC>
	<DOCNO>NCT00115154</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy imiquimod 5 % cream compare vehicle cream treatment Actinic Keratosis ( AK ) arm and/or hand cream apply daily 2 day per week 16 week .</brief_summary>
	<brief_title>Study Assess Safety Efficacy Imiquimod 5 % Cream Treatment Actinic Keratosis Arms Hands</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>18 year age Have AK arm hand Discontinuation sun tan use tan bed Discontinuation use moisturizers , body oil , overthecounter retinol product product contain alpha beta hydroxy acid treatment surround area Withholding use sunscreen treatment area 24 hour prior study visit 8 hour apply study cream Postponement treatment nonstudy AK lesion anywhere arm treat study participation complete Subjects must evidence systemic cancer immunosuppression unstable health condition Participation another clinical study Have previously receive treatment imiquimod within treatment area Have squamous cell carcinoma ( SCC ) , basal cell carcinoma ( BCC ) , malignancy treatment surround area require treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Actinic Keratosis</keyword>
	<keyword>AK</keyword>
	<keyword>3M Pharmaceuticals</keyword>
	<keyword>Aldara</keyword>
	<keyword>Imiquimod</keyword>
	<keyword>Actinic Keratosis ( AK )</keyword>
</DOC>